Prostate Cancer Treatment Platform

Anatoly Dritschilo, MD, FACR, is a distinguished physician-scientist with over four decades of leadership in translational medicine and experimental therapeutics. A board-certified Radiation Oncologist, he has treated thousands of patients with prostate cancer and pioneered advancements in radiation therapy, drug discovery, and precision medicine. For any inquiries about his work, feel free to contact us as health matters are of utmost importance to him.

At Georgetown University School of Medicine and the MedStar Georgetown University Hospital, Dr. Dritschilo held key roles including Chairman of Radiation Medicine, Director of Radiation Oncology, Hospital Medical Director, and Interim Director of the Lombardi Comprehensive Cancer Center. His prolific research career includes over 260 scientific publications and 50 U.S. and international patents. He maintains his Georgetown University academic affiliation as Emeritus Professor in Radiation Medicine and is an elected Fellow of both the American College of Radiology and the National Academy of Inventors. His work has attracted substantial funding from the NIH, the pharmaceutical industry, and capital markets to launch biopharmaceutical ventures that translate lab discoveries into clinical solutions.

He co-founded NeoPharm, Inc. (NEOL) and Shuttle Pharmaceuticals Holdings, Inc. (SHPH), guiding both from startup to publicly traded companies. In 2025, he joined longtime collaborator Dr. Alan Kozikowski to co-found Prostate Theranostics, Inc., focusing on developing next-generation therapeutics to improve outcomes for patients undergoing prostate cancer treatment.